Karson S. Putt

Dr. Karson S. Putt


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

26 August 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CHChien Dinh Huynh
Chien Dinh Huynh
APAntonella Pantaleo
Antonella Pantaleo
KKKristina R. Kesely
Kristina R. Kesely
PNPanae Noomuna
Panae Noomuna
KPKarson S. Putt
Karson S. Putt
FTFrancesco M. Turrini
Francesco M. Turrini
To egress from its erythrocyte host, the malaria parasite, Plasmodium falciparum, must destabilize the erythrocyte membrane by activating an erythrocyte tyrosine kinase. Because imatinib inhibits erythrocyte tyrosine kinases and because imatinib has a good safety profile, we elected to determine whether coadministration of imatinib with standard of care (SOC) might be both well tolerated and therapeutically efficacious in malaria patients. Patients with uncomplicated P. falciparum malaria from a region in Vietnam where one third of patients experience delayed parasite clearance (DPC; continued parasitemia after 3 d of therapy) were treated for 3 d with either the region’s SOC (40 mg dihydroartemisinin + 320 mg piperaquine/d) or imatinib (400 mg/d) + SOC. Imatinib + SOC–treated participants exhibited no increase in number or severity of adverse events, a significantly accelerated decline in parasite density and pyrexia, and no DPC. Surprisingly, these improvements were most pronounced in patients with the highest parasite density, where serious complications and death are most frequent. Imatinib therefore appears to improve SOC therapy, with no obvious drug-related toxicities.

19 June 2021 in Molecules
Verified
Journal Article
Open access
PDF file
SMSakkarapalayam M. Mahalingam
Sakkarapalayam M. Mahalingam
KPKarson S. Putt
Karson S. Putt
MSMadduri Srinivasarao
Madduri Srinivasarao
Philip LowPhilip Low
Philip Low
The inadvertent severing of a ureter during surgery occurs in as many as 4.5% of colorectal surgeries. To help prevent this issue, several near-infrared (NIR) dyes have been developed to assist surgeons with identifying ureter location. However, the majority of these dyes exhibit at least some issue that precludes their widespread usage such as high levels of uptake in other tissues, overlapping emission wavelengths with other NIR dyes used for other fluorescence-guided surgeries, and/or rapid excretion times through the ureters. To overcome these limitations, we have synthesized and characterized the spectral properties and biodistribution of a new series of PEGylated UreterGlow derivatives. The most promising dye, UreterGlow-11 was shown to almost exclusively excrete through the kidneys/ureters with detectable fluorescence observed for at least 12 h. Additionally, while the excitation wavelength is similar to that of other NIR dyes used for cancer resections, the emission is shifted by ~30 nm allowing for discrimination between the different fluorescence-guided surgery probes. In conclusion, these new UreterGlow dyes show promising optical and biodistribution characteristics and are good candidates for translation into the clinic.

1 June 2021 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CVChelvam Venkatesh
Chelvam Venkatesh
DDDerek D. Doorneweerd
Derek D. Doorneweerd
WXWei Xia
Wei Xia
KPKarson S. Putt
Karson S. Putt
Philip LowPhilip Low
Philip Low

1 November 2020 in Biophysical Journal
Verified
Journal Article
Closed access
GKGayani C. Kodippili
Gayani C. Kodippili
KGKatie Giger
Katie Giger
KPKarson S. Putt
Karson S. Putt
Philip LowPhilip Low
Philip Low

29 March 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RVRamya Visvanathan
Ramya Visvanathan
TUTadanobu Utsuki
Tadanobu Utsuki
DBDaniel E. Beck
Daniel E. Beck
WCW. Brent Clayton
W. Brent Clayton
ELEmma Lendy
Emma Lendy
KPKarson S. Putt
Karson S. Putt
The activities of the phospholipase C gamma (PLCγ) 1 and 2 enzymes are essential for numerous cellular processes. Unsurprisingly, dysregulation of PLCγ1 or PLCγ2 activity is associated with multiple maladies including immune disorders, cancers, and neurodegenerative diseases. Therefore, the modulation of either of these two enzymes has been suggested as a therapeutic strategy to combat these diseases. To aid in the discovery of PLCγ family enzyme modulators that could be developed into therapeutic agents, we have synthesized a high-throughput screening-amenable micellular fluorogenic substrate called C16CF3-coumarin. Herein, the ability of PLCγ1 and PLCγ2 to enzymatically process C16CF3-coumarin was confirmed, the micellular assay conditions were optimized, and the kinetics of the reaction were determined. A proof-of-principle pilot screen of the Library of Pharmacologically Active Compounds 1280 (LOPAC1280) was performed. This new substrate allows for an additional screening methodology to identify modulators of the PLCγ family of enzymes.